Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.35 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367647 | 0.91 | P2RX1 (0.39) | ALDH1A1AKR1B10AKR1B1KDM4EPOLB | |
| SCHEMBL1368543 | 0.88 | CA12 (0.47) | ALDH1A1AKR1B10AKR1B1KDM4EPOLB | |
| SCHEMBL1367470 | 0.82 | PIK3CA (0.38) | ALDH1A1AKR1B1KDM4EHPGDCYP3A4 | |
| SCHEMBL1368332 | 0.80 | TSHR (0.54) | ALDH1A1KDM4EPOLBCYP1A2TSHR | |
| SCHEMBL1370309 | 0.79 | VCAM1 (0.36) | ALDH1A1AKR1B10AKR1B1KDM4EPOLB | |
| SCHEMBL1368421 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL830702 | 0.77 | TXNRD1 (0.40) | ALDH1A1AKR1B10AKR1B1KDM4EPOLB | |
| SCHEMBL1366882 | 0.77 | DAO (0.42) | ALDH1A1AKR1B10AKR1B1KDM4EPOLB | |
| SCHEMBL1365704 | 0.75 | MEN1 (0.50) | ALDH1A1HPGDCYP3A4MEN1KMT2A | |
| SCHEMBL1368096 | 0.74 | CA12 (0.45) | ALDH1A1AKR1B1KDM4EHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| US-8067461-B2 | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | ALDH1A1 617/4885AKR1B10 1171/4885AKR1B1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.